JW Pharmaceutical Corporation (001065.KS)
KRW 29450.0
(-1.01%)
KRW 29450.0
(-1.01%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 335.67 Billion KRW | 16.57% |
| 2022 | 287.95 Billion KRW | 22.86% |
| 2021 | 234.37 Billion KRW | 32.02% |
| 2020 | 177.52 Billion KRW | 10.18% |
| 2019 | 161.11 Billion KRW | -18.23% |
| 2018 | 197.04 Billion KRW | 4.46% |
| 2017 | 188.63 Billion KRW | 8.82% |
| 2016 | 173.34 Billion KRW | 7.92% |
| 2015 | 160.62 Billion KRW | 6.18% |
| 2014 | 151.27 Billion KRW | 4.7% |
| 2013 | 144.48 Billion KRW | 12.02% |
| 2012 | 128.97 Billion KRW | -12.85% |
| 2011 | 147.99 Billion KRW | -8.36% |
| 2010 | 161.49 Billion KRW | -13.2% |
| 2009 | 186.05 Billion KRW | -2.44% |
| 2008 | 190.71 Billion KRW | 4.24% |
| 2007 | 182.95 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 83.02 Billion KRW | -11.88% |
| 2024 Q2 | 71.11 Billion KRW | -14.34% |
| 2023 Q3 | 81.97 Billion KRW | -1.94% |
| 2023 Q2 | 83.59 Billion KRW | 10.35% |
| 2023 Q1 | 75.75 Billion KRW | -14.69% |
| 2023 FY | 335.67 Billion KRW | 16.57% |
| 2023 Q4 | 94.22 Billion KRW | 14.95% |
| 2022 Q4 | 88.79 Billion KRW | 27.41% |
| 2022 FY | 287.95 Billion KRW | 22.86% |
| 2022 Q1 | 64.28 Billion KRW | -1.94% |
| 2022 Q2 | 65.17 Billion KRW | 1.39% |
| 2022 Q3 | 69.69 Billion KRW | 6.93% |
| 2021 Q1 | 58.9 Billion KRW | 10.25% |
| 2021 Q2 | 55.67 Billion KRW | -5.49% |
| 2021 Q3 | 54.23 Billion KRW | -2.59% |
| 2021 FY | 234.37 Billion KRW | 32.02% |
| 2021 Q4 | 65.55 Billion KRW | 20.88% |
| 2020 Q4 | 53.43 Billion KRW | 27.68% |
| 2020 Q1 | 43.23 Billion KRW | 79.14% |
| 2020 FY | 177.52 Billion KRW | 10.18% |
| 2020 Q3 | 41.84 Billion KRW | 7.26% |
| 2020 Q2 | 39.01 Billion KRW | -9.75% |
| 2019 Q1 | 45.02 Billion KRW | 28.39% |
| 2019 FY | 161.11 Billion KRW | -18.23% |
| 2019 Q2 | 47.23 Billion KRW | 4.91% |
| 2019 Q4 | 24.13 Billion KRW | -46.05% |
| 2019 Q3 | 44.73 Billion KRW | -5.29% |
| 2018 Q4 | 35.06 Billion KRW | -44.9% |
| 2018 Q3 | 63.63 Billion KRW | 28.78% |
| 2018 Q2 | 49.41 Billion KRW | 0.98% |
| 2018 Q1 | 48.92 Billion KRW | -3.85% |
| 2018 FY | 197.04 Billion KRW | 4.46% |
| 2017 Q4 | 50.88 Billion KRW | 8.48% |
| 2017 Q3 | 46.9 Billion KRW | 3.83% |
| 2017 Q2 | 45.17 Billion KRW | -1.04% |
| 2017 Q1 | 45.65 Billion KRW | 1.01% |
| 2017 FY | 188.63 Billion KRW | 8.82% |
| 2016 Q3 | 43.74 Billion KRW | 2.43% |
| 2016 Q2 | 42.71 Billion KRW | 2.46% |
| 2016 Q1 | 41.68 Billion KRW | -2.45% |
| 2016 FY | 173.34 Billion KRW | 7.92% |
| 2016 Q4 | 45.2 Billion KRW | 3.32% |
| 2015 Q1 | 37.07 Billion KRW | -17.77% |
| 2015 Q4 | 42.72 Billion KRW | 3.82% |
| 2015 Q3 | 41.15 Billion KRW | 3.78% |
| 2015 Q2 | 39.66 Billion KRW | 6.97% |
| 2015 FY | 160.62 Billion KRW | 6.18% |
| 2014 FY | 151.27 Billion KRW | 4.7% |
| 2014 Q4 | 45.08 Billion KRW | 13.62% |
| 2014 Q3 | 39.68 Billion KRW | 29.91% |
| 2014 Q2 | 30.54 Billion KRW | -15.05% |
| 2014 Q1 | 35.95 Billion KRW | -2.97% |
| 2013 Q4 | 37.05 Billion KRW | 6.77% |
| 2013 FY | 144.48 Billion KRW | 12.02% |
| 2013 Q1 | 32.91 Billion KRW | 2.99% |
| 2013 Q2 | 39.8 Billion KRW | 20.95% |
| 2013 Q3 | 34.7 Billion KRW | -12.81% |
| 2012 Q4 | 31.95 Billion KRW | -4.88% |
| 2012 FY | 128.97 Billion KRW | -12.85% |
| 2012 Q3 | 33.59 Billion KRW | 21.3% |
| 2012 Q1 | 35.72 Billion KRW | 0.0% |
| 2012 Q2 | 27.69 Billion KRW | -22.48% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q2 | 40.27 Billion KRW | 13.42% |
| 2011 Q1 | 35.5 Billion KRW | -10.84% |
| 2011 Q3 | 37.49 Billion KRW | -6.89% |
| 2011 FY | 147.99 Billion KRW | -8.36% |
| 2010 Q4 | 39.82 Billion KRW | 9.6% |
| 2010 FY | 161.49 Billion KRW | -13.2% |
| 2010 Q1 | 43.36 Billion KRW | -7.53% |
| 2010 Q3 | 36.33 Billion KRW | -13.45% |
| 2010 Q2 | 41.97 Billion KRW | -3.19% |
| 2009 Q2 | 46.58 Billion KRW | -8.65% |
| 2009 Q4 | 46.89 Billion KRW | 12.74% |
| 2009 Q3 | 41.59 Billion KRW | -10.71% |
| 2009 Q1 | 50.99 Billion KRW | 20.5% |
| 2009 FY | 186.05 Billion KRW | -2.44% |
| 2008 Q2 | 53.53 Billion KRW | 8.52% |
| 2008 Q3 | 45.52 Billion KRW | -14.98% |
| 2008 FY | 190.71 Billion KRW | 4.24% |
| 2008 Q4 | 42.31 Billion KRW | -7.03% |
| 2008 Q1 | 49.33 Billion KRW | 14.34% |
| 2007 Q4 | 43.14 Billion KRW | -1.72% |
| 2007 Q1 | 44.76 Billion KRW | 0.0% |
| 2007 Q2 | 51.14 Billion KRW | 14.24% |
| 2007 FY | 182.95 Billion KRW | 0.0% |
| 2007 Q3 | 43.9 Billion KRW | -14.15% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -621.797% |
| Dong-A Socio Holdings Co., Ltd. | 364.1 Billion KRW | 7.81% |
| Ildong Holdings Co., Ltd. | 198.88 Billion KRW | -68.775% |
| HANDOK Inc. | 151.36 Billion KRW | -121.761% |
| Kukje Pharma Co., Ltd. | 67.22 Billion KRW | -399.329% |
| Yuhan Corporation | 564.5 Billion KRW | 40.537% |
| Dong-A ST Co., Ltd. | 322.21 Billion KRW | -4.177% |
| SAMSUNG PHARM. Co., LTD. | 23.74 Billion KRW | -1313.53% |
| Hanmi Pharm. Co., Ltd. | 835.85 Billion KRW | 59.841% |
| Hanall Biopharma Co.,Ltd | 75.03 Billion KRW | -347.327% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | -68.712% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.64 Billion KRW | -725.77% |
| MYUNGMOON Pharm co.,Ltd | 94.51 Billion KRW | -255.15% |
| Hana Pharm Co., Ltd. | 140.85 Billion KRW | -138.309% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -621.797% |
| Ilsung Pharmaceuticals Co., Ltd. | 34.71 Billion KRW | -866.915% |
| REYON Pharmaceutical Co., Ltd. | 76.81 Billion KRW | -336.969% |
| Aprogen pharmaceuticals,Inc. | -12.04 Billion KRW | 2886.675% |
| JW Holdings Corporation | 446.15 Billion KRW | 24.764% |
| Ildong Pharmaceutical Co., Ltd. | 207.53 Billion KRW | -61.739% |
| Chong Kun Dang Pharmaceutical Corp. | 655.34 Billion KRW | 48.779% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -326.956% |
| Hyundai Pharmaceutical Co., Ltd. | 75.23 Billion KRW | -346.147% |
| Samil Pharmaceutical Co.,Ltd | 72.21 Billion KRW | -364.845% |
| Jeil Pharmaceutical Co.,Ltd | 183.81 Billion KRW | -82.615% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -621.797% |
| Kwang Dong Pharmaceutical Co., Ltd. | 295.11 Billion KRW | -13.741% |
| Daewoong pharmaceutical Co.,Ltd | 681.55 Billion KRW | 50.749% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 0.0% |
| Yuhan Corporation | 564.5 Billion KRW | 40.537% |
| Jeil Pharma Holdings Inc | 201.82 Billion KRW | -66.321% |
| Yungjin Pharm. Co., Ltd. | 70.93 Billion KRW | -373.184% |
| Suheung Co., Ltd. | 99.02 Billion KRW | -238.97% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 0.0% |
| Samjin Pharmaceuticals Co., Ltd. | 145.89 Billion KRW | -130.083% |
| Korea United Pharm Inc. | 173.48 Billion KRW | -93.484% |
| CKD Bio Corp. | 5.01 Billion KRW | -6599.637% |
| Daewon Pharmaceutical Co., Ltd. | 254.23 Billion KRW | -32.034% |
| Dongwha Pharm.Co.,Ltd | 184.12 Billion KRW | -82.307% |
| Whan In Pharm Co.,Ltd. | 98.12 Billion KRW | -242.085% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -326.956% |
| Chong Kun Dang Holdings Corp. | 371.49 Billion KRW | 9.644% |
| Boryung Corporation | 333.26 Billion KRW | -0.721% |
| Bukwang Pharmaceutical Co., Ltd. | 50.04 Billion KRW | -570.733% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | -68.712% |
| JW Lifescience Corporation | 51.32 Billion KRW | -554.013% |